Latest Us Market Entry News

PainChek Ltd has secured FDA De Novo clearance for its Adult App, marking a pivotal entry into the US long-term care market and setting the stage for global expansion including its Infant App.

Proteomics International secures a key Medicare reimbursement rate for its PromarkerD test, a predictive diagnostic for diabetic kidney disease, marking a critical step in its US commercial rollout.

Clarity Pharmaceuticals has raised $203 million to accelerate its copper-64 and copper-67 radiopharmaceutical pipeline, targeting prostate and neuroendocrine cancers with multiple FDA Fast Track trials underway.

Echo IQ has completed a pivotal clinical validation of its EchoSolv HF software at the Mayo Clinic, achieving outstanding accuracy ahead of its FDA submission. This milestone sets the stage for potential US market entry into a $60 billion heart failure diagnostics sector.

Great Northern Minerals has secured a listing on the OTCQB Venture Market, enhancing its access to North American investors as it advances critical minerals projects in the US.

Decidr AI Industries has announced a strategic acquisition of Delaware-based Sugarwork Inc., marking its official entry into the US market and enhancing its Agentic AI platform with advanced knowledge transfer capabilities.

Tungsten Mining has secured a listing on the US OTCQB exchange and launched a Denver office, marking a strategic push into North America’s critical minerals market.

Red Mountain Mining is set to list on the US OTCQB exchange, offering US investors direct access to its shares while expanding its portfolio of critical antimony assets in key US mining districts.

Terra Critical Minerals (ASX, T92) broadens its critical minerals portfolio with new US initiatives and promising exploration in New South Wales and Canada. The company also pursues a US OTC listing to tap North American capital.

PainChek Ltd has achieved a pivotal FDA De Novo clearance for its AI-driven Adult pain assessment app, unlocking the US market and driving its annual recurring revenue to $5.6 million. The company also launched its Infant app, targeting a vast global market of pre-verbal children.

EZZ Life Science Holdings reported a 25% drop in Q1 receipts, driven by seasonal softness and campaign timing, while accelerating its US market entry and launching three new health supplements.

LTR Pharma has made significant strides towards its US market debut with ROXUS, bolstered by expert appointments and peer-reviewed clinical data validating its rapid-onset ED treatments.